GSK plc (GLAXF) Financials
GLAXF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 83.0 billion | 60.0 billion |
| Dec. 31, 2025 | 82.1 billion | 60.6 billion |
| Sept. 30, 2025 | 82.5 billion | 61.3 billion |
| June 30, 2025 | 81.4 billion | 61.7 billion |
GLAXF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 921.4 million | ? |
| Dec. 31, 2025 | 2.0 billion | ? |
| Sept. 30, 2025 | 2.6 billion | ? |
| June 30, 2025 | 2.0 billion | ? |
GLAXF Net Income
| Date | Net Income |
|---|---|
| March 31, 2026 | 2.4 billion |
| Dec. 31, 2025 | 854.5 million |
| Sept. 30, 2025 | 2.7 billion |
| June 30, 2025 | 2.3 billion |
GLAXF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 4.5 billion | - | - |
| Dec. 31, 2025 | 4.6 billion | 19.8 billion | 1.1 billion |
| Sept. 30, 2025 | 4.4 billion | 20.0 billion | - |
| June 30, 2025 | 5.0 billion | - | - |
GLAXF Shares Outstanding
GLAXF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 584.8 million | 2.2 billion | 2.8 billion | - |
| Dec. 31, 2025 | 769.9 million | 3.1 billion | 3.6 billion | - |
| Sept. 30, 2025 | 428.4 million | 1.7 billion | 2.2 billion | - |
| June 30, 2025 | 869.1 million | 2.8 billion | 2.9 billion | - |
GLAXF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 10.1 billion | 2.5 billion |
| Dec. 31, 2025 | 11.6 billion | 3.5 billion |
| Sept. 30, 2025 | 8.5 billion | 2.3 billion |
| June 30, 2025 | 11.0 billion | 3.0 billion |
GLAXF
Price: $25.31
Dividend Yield: 3.48%
Payout Ratio: 51.48%
Earnings Per Share: 1.93 USD
P/E Ratio: 12.96
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - General
Country: United Kingdom
Market Capitalization: 103.3 billion
Average Dividend Frequency: 8
Years Paying Dividends: 23
DGR3: 11.79%
DGR5: 7.08%
DGR10: 1.30%
DGR20: 5.77%